Nanomedx

Nanomedx has developed a novel carbon-based nanoparticle which can be utilised for multiple clinical applications to address some of the most pressing challenges in modern medicine. The Nanomedx platform is built on the scientific discovery of Professor Steven Wise and his team at University of Sydney. The technology and the associated IP has been further researched and adapted for clinical applications at the Heart Research Institute (HRI) in Sydney and has received funding from the National Foundation for Medical Research and Innovation (NFMRI) and the Targeted Translation Research Accelerator (TTRA). Nanomedx has a clear objective of establishing itself as the global leader in medical nanoparticle technology and ensuring that the myriad therapies developed on the back of the platform will result in unprecedented clinical benefits for patients around the world.

• Employees4
• Founded2021